Hemophilia A Treatment

The treatment approach to hemophilia depends on the type of hemophilia a person has and its severity. There are two forms of this condition, hemophilia A and hemophilia B, although most cases are hemophilia A.

There are two main approaches to the treatment of hemophilia A. These include:

  • Preventive treatment - This refers to the regular medications that are taken to prevent episodes of bleeding and subsequent complications such as joint damage.
  • Episodic treatment - These treatments are used to manage episodes of prolonged bleeding.

Preventive treatment

Over recent decades, genetically engineered clotting factor medications have been made available to help replenish clotting factors and prevent prolonged bleeding. This medication is administered as an injection on a regular basis in the case of severe hemophilia. Children with hemophilia A are often taught to give self-injections so as to minimize the need for hospital admissions as they pass into adulthood. An implantable port is sometimes surgically placed under the skin (e.g. Port-a-Cath). This is connected to a blood vessel near the heart and can be used each time injections are given. These preventive medications need to be continued lifelong to prevent bleeding episodes.

For hemophilia A, regular injections of a medication called octocog alfa are administered. This is an engineered version of clotting factor VIII, the clotting factor people with hemophilia A are deficient in. Patients are advised to have an injection every 48 hours. Side effects include an itchy skin rash and redness at the injection site.

Epsidodic treatment

In mild or moderate hemophilia, regular preventive treatment is not always required. These patients may only require treatment to manage individual episodes of bleeding. For people with hemophilia A, this may be achieved with injections of octocog alfa or another medication called desmopressin. Desmopressin is a synthetic hormone that stimulates the production of clotting factor VIII.

Further Reading

Last Updated: Feb 25, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, February 25). Hemophilia A Treatment. News-Medical. Retrieved on July 19, 2024 from https://www.news-medical.net/health/Haemophilia-A-Treatment.aspx.

  • MLA

    Mandal, Ananya. "Hemophilia A Treatment". News-Medical. 19 July 2024. <https://www.news-medical.net/health/Haemophilia-A-Treatment.aspx>.

  • Chicago

    Mandal, Ananya. "Hemophilia A Treatment". News-Medical. https://www.news-medical.net/health/Haemophilia-A-Treatment.aspx. (accessed July 19, 2024).

  • Harvard

    Mandal, Ananya. 2023. Hemophilia A Treatment. News-Medical, viewed 19 July 2024, https://www.news-medical.net/health/Haemophilia-A-Treatment.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.